Incannex (IXHL) reports first patient dosed in DReAMzz Phase 2 study
Incannex announces the first patient is dosed in its DReAMzz Phase 2 study of IHL-42X; the source provides no additional dosing schedule, results, or catalyst details.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.